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1 The electrophysiological eects of dronedarone, a new nonionidated analogue of amiodarone
were studied after chronic and acute administration in dog Purkinje fibres, papillary muscle and
isolated ventricular myocytes, and compared with those of amiodarone by applying conventional
microelectrode and patch-clamp techniques.
2 Chronic treatment with dronedarone (2625 mg71 kg71 day p.o. for 4 weeks), unlike chronic
administration of amiodarone (50 mg71 kg71 day p.o. for 4 weeks), did not lengthen significantly the
QTc interval of the electrocardiogram or the action potential duration (APD) in papillary muscle.
After chronic oral treatment with dronedarone a small, but significant use-dependent Vmax block
was noticed, while after chronic amiodarone administration a strong use-dependent Vmax depression
was observed.
3 Acute superfusion of dronedarone (10 mM), similar to that of amiodarone (10 mM), moderately
lengthened APD in papillary muscle (at 1 Hz from 239.6+5.3 to 248.6+5.3 ms, n=13, P50.05),
but shortened it in Purkinje fibres (at 1 Hz from 309.6+11.8 to 287.1+10.8 ms, n=7, P50.05).
4 Both dronedarone (10 mM) and amiodarone (10 mM) superfusion reduced the incidence of early
and delayed afterdepolarizations evoked by 1 mM dofetilide and 0.2 mM strophantidine in Purkinje
fibres.
5 In patch-clamp experiments 10 mM dronedarone markedly reduced the L-type calcium current
(76.5+0.7 %, n=6, P50.05) and the rapid component of the delayed rectifier potassium current
(97+1.2 %, n=5, P50.05) in ventricular myocytes.
6 It is concluded that after acute administration dronedarone exhibits eects on cardiac electrical
activity similar to those of amiodarone, but it lacks the ‘amiodarone like’ chronic electro-
physiological characteristics.
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Introduction
The CAST (CAST investigators, 1989) and the SWORD
(Waldo et al., 1996) studies showed that some Class I/C
antiarrhythmic drugs, such as flecainide and encainide, and a
‘pure’ Class III drug, D-sotalol, significantly increased the
proarrhythmia related postinfarction mortality. These fail-
ures in the antiarrhythmic therapy shifted interest more
toward amiodarone, a drug which is a particularly eective
antiarrhythmic agent (Link et al., 1995) and, in contrast
with flecainide and D-sotalol, did not seem to increase
(Julian et al., 1997) or even reduce (Pfisterer et al., 1992)
postinfarction mortality in dierent multicenter clinical
trials.
Amiodarone was first recognized to lengthen cardiac action
potential duration after chronic treatment (Singh & Vaughan
Williams, 1970) and was, therefore, classified as a Class III
antiarrhythmic drug (Vaughan Williams, 1975). Later it
became evident that amiodarone has multiple actions,
including use-dependent block of the inward sodium (Mason
et al., 1984; Varro´ et al., 1985; Follmer et al., 1987) and
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calcium (Nishimura et al., 1989) currents, block of the a and
b adrenoceptors (Polster & Broekhuysen, 1976) and it may
also have some other yet less well explored properties.
Amiodarone, in contrast with pure Class III drugs, decreased
dispersion of repolarization between ventricular epicardial,
endocardial M cells (Sicouri et al., 1997) and Purkinje fibres
(Papp et al., 1996). These features of amiodarone may, at
least partly, explain the low proarrhythmic potential of the
drug (Lazzara, 1989).
Amiodarone, however, has a relatively wide range of
extracardiac side eects (Harris et al., 1983) which has been
attributed to the iodine in its chemical structure and can
significantly diminish its use in clinical practice. Therefore, a
noniodinated benzofuran analogue of amiodarone, dronedar-
one (SR 33589) was developed and tested in in vitro (Moro et
al., 1999; Sun et al., 1999) and in vivo (Manning et al., 1995b)
electrophysiological experiments and in experimental arrhyth-
mia models (Finance et al., 1995; Manning et al., 1995a).
These latter studies revealed that dronedarone, like amiodar-
one, possesses strong antiarrhythmic potency. In a recent in
vitro study performed in rabbit papillary muscle it was found
that dronedarone, both after long-term treatment and after
acute application, exerted cardiac electrophysiological eects
similar to those of amiodarone (Sun et al., 1999). This led to
the conclusion that the electrophysiological eects of
dronedarone are similar to those of amiodarone but more
potent, despite deletion of iodine from its molecular
structure, a finding of importance for the development of
future Class III antiarrhythmic compounds (Sun et al., 1999).
However, our results obtained in cardiac preparations
isolated from dog hearts and presented in this study showed
that the eect of chronic dronedarone treatment strikingly
diers from that of long-term administration of amiodarone.
Therefore we favour an opposite conclusion, i.e. the unique
chronic cardiac electrophysiological eects of amiodarone
might be due to the inhibition of the cardiac thyroid
receptors (Kodama et al., 1999) which may relate to the
iodine in the molecular structure of the compound.
Methods
All experiments were conducted in compliance with the Guide
for the Care and Use of Laboratory Animals (USA NIH
publication No 85-23, revised 1985). The protocols were
approved by the review board of Committee on Animal
Research of the University of Szeged (54/1999 OEj).
Conventional microelectrode technique
Adult mongrel dogs (8 – 14 kg) of either sex were used.
Following anaesthesia (sodium pentobarbital, 30 mg kg71
administered intravenously), the heart of each animal was
rapidly removed through right lateral thoracotomy. The
hearts were immediately rinsed in oxygenated Tyrode’s
solution containing (in mM): NaCl, 115; KCl, 4; CaCl2, 1.8;
MgCl2, 1; NaHCO3, 20; and glucose, 11. The pH of this
solution was 7.40 to 7.45 when gassed with 95% O2 and 5%
CO2 at 378C. Purkinje strands obtained from either ventricle
or the tip of the papillary muscles from the right ventricle
were individually mounted in a tissue chamber (volume &
50 ml). Each ventricular preparation was initially stimulated
(HSE (Hugo Sachs Elektronik) stimulator type 215/II,
March-Hugstetten, Germany) at a basic cycle length of
1000 ms (frequency=1 Hz), Purkinje fibre preparations were
stimulated at basic cycle length of 500 ms (2 Hz) using 2 ms
long rectangular constant voltage pulses isolated from ground
and delivered across bipolar platinum electrodes in contact
with the preparation. At least 1 h was allowed for each
preparation to equilibrate while they were continuously
superfused with Tyrode’s solution. Temperature of the
superfusate was kept constant at 378C. Transmembrane
potentials were recorded using conventional microelectrode
recording techniques. Microelectrodes filled with 3 M KCl
and having tip resistances of 5 – 20 mO were connected to the
input of a high impedance electrometer (HSE microelectrode
amplifier type 309), which was referenced to the ground. The
first derivative of transmembrane potentials (Vmax) was
electronically derived by an HSE dierentiator (type 309).
The voltage outputs from all amplifiers were displayed on a
dual beam memory oscilloscope (Tektronix 2230 100 MHz
digital storage oscilloscope, Beaverton, OR, U.S.A.).
The maximum diastolic potential (MDP), action potential
amplitude (APA), and APD measured at 50 and 90%
repolarization (APD50 – 90) were obtained using a software
developed in our department (HSE-APES) on an IBM 386
microprocessor base personal computer connected to the
digital output of the oscilloscope. Dogs were orally treated
with 50 mg kg71 amiodarone or 2625 mg kg71 dronedarone
every day for 4 weeks. Control dogs were kept in similar
condition but they did not receive treatment. Electrocardio-
gram recordings (limb I – III leads) were taken in the
conscious animals before and after the 4 weeks of treatment.
In those experiments in which the acute direct eects of the
drugs were studied, after the control measurements, the
preparations had been superfused for 60 min with Tyrode’s
solution containing 10 mM of the compounds before the
electrophysiologic measurements were commenced. Both
amiodarone and dronedarone were dissolved in 100% DMSO
to make 10 mM stock solutions. The stock solutions were
further diluted in the tissue bath to obtain the desired final
drug concentrations.
Whole cell configuration of the patch-clamp technique
Ventricular myocytes were enzymatically dissociated from
hearts of mongrel dogs of either sex weighing 10 – 20 kg
following anaesthesia (sodium pentobarbital, 30 mg·kg71 i.v.)
as described earlier in detail (Varro´ et al., 2000).
One drop of cell suspension was placed within a
transparent recording chamber mounted on the stage of an
inverted microscope (TMS, Nikon, Tokyo, Japan), and
individual myocytes were allowed to settle and adhere to
the chamber bottom for at least 5 min before superfusion was
initiated. Only rod shape cells with clear striations were used.
HEPES buered Tyrode’s solution served as the normal
superfusate. This solution contained (mM): NaCl 144,
NaH2PO4 0.33, KCl 4.0, CaCl2 1.8, MgCl2 0.53, Glucose
5.5, and HEPES 5.0 at pH of 7.4.
Patch-clamp micropipettes were fabricated from borosili-
cate glass capillaries (Clark, Reading, U.K.) using a P-97
Flaming/Brown micropipette puller (Sutter Co., Novato, CA,
U.S.A.). These electrodes had resistances between 1.5 –
2.5 MO when filled with pipette solution containing (in
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mM): K-aspartate 100, KCl 45, ATP 3, MgCl2 1, EGTA 10
and HEPES 5. The pH of this solution was adjusted to 7.2 by
KOH. In case of measuring K+ currents, nisoldipine (1 mM)
(obtained as a gift from the Bayer AG, Leverkusen,
Germany) was placed in the external solution to eliminate
inward Ca2+ current (ICa). The rapid IKr and slow IKs
components of the delayed rectifier potassium current were
separated by using the selective IKr blocker E-4031 (1 mM) or
the IKs blocker chromanol 293B (30 mM). When Ca2+ current
was measured the pipette solution contained (in mM): CsCl
110, CsOH 40, EGTA 10, HEPES 10, TEACl 20, ATP 5 (pH
was adjusted to 7.2 by CsOH). Membrane currents were
recorded with an Axopatch-1D amplifier (Axon Instruments,
Foster City, CA, U.S.A.) using the whole-cell configuration
of the patch-clamp technique. After establishing a high (1 – 10
Gohm) resistance seal by gentle suction, the cell membrane
beneath the tip of the electrode was disrupted by suction or
by application of 1.5 V electrical pulses for 1 – 5 ms. The
series resistance was typically 4 – 8 MO before compensation
(50 – 80%, depending on the voltage protocols). Experiments
where the series resistance was high, or substantially
increased during measurement, were discarded. Membrane
currents were digitised using a 333 kHz analogue-to-digital
converter (Digidata 1200, Axon Instruments) under software
control (pClamp 6.0, Axon Instruments). Analyses were
performed using Axon (pClamp 6.0) software after low-pass
filtering at 1 kHz. All patch-clamp data were collected at
378C.
Determination of plasma and tissue levels of dronedarone
and amiodarone
Plasma and cardiac tissue levels of dronedarone and
amiodarone in the chronically treated dogs were measured
by the Bioanalysis Laboratory, in the Preclinical Depart-
ment for Pharmacokinetics and Metabolism, at Sanofi-
Synthelabo Research in Montpellier (France). After a
liquid/liquid extraction, dronedarone plasma levels were
determined using High Performance Liquid Chromatogra-
phy (HPLC) (ultra violet detection 290 nm). Plasma levels
of dronedarone were calculated by applying a daily
prepared calibration curve using untreated dog plasma.
The regressions were least squares linear and not forced
through the origin and weighted on 1·y72. The following
concentrations were investigated: 0.020, 0.050, 0.100, 0.200,
0.500, 0.800 and 1.000 mg l71. Similarly (ultra violet
detection at 254 nm) amiodarone and desethylamiodarone
plasma levels were calculated utilizing a daily prepared
calibration curve using untreated dog plasma. The regres-
sions were least squares linear regression not forced
through the origin. The concentrations investigated were:
0.050, 0.100, 0.200, 0.500, 1.0, 2.0, 3.0 and 4.0 mg l71.
Heart samples were homogenized in Tris Buer pH=7.4
and tissue drug levels were determined using HLPC, after
liquid/liquid extraction with ultra violet detection at 290 nm
for dronedarone and 254 nm for amiodarone. Dronedarone
cardiac tissue levels were calculated by applying a daily
prepared calibration curve using untreated dog heart. The
regressions were least squares linear regression not forced
through the origin and weighted on 1·x72. The following
concentrations were investigated: 0.040, 0.080, 0.200, 0.400,
0.800, 1.6, 2.0, 3.0, 4.0 and 6 mg kg71. Cardiac tissue levels
of amiodarone and desethylamiodarone were calculated
using a daily prepared calibration curve using untreated
dog heart. The regressions used were least squares linear
not forced through the origin and weighted on 1·x72. The
concentrations applied were as follows: 0.150, 0.300, 0.600,
1.6, 3.2, 6.3, and 12.6 mg kg71.
Determination of plasma levels of thyroid hormones
Plasma thyroxine (T4), triiodothyronine (T3) and reverse
triiodothyronine (rT3) were measured with conventional RIA
kits (T4: GammaCoatTM M[125I] Total T4 RIA kit, DiaSorin;
T3: GammaCoat
TM [125I] T3 RIA kit, DiaSorin; rT3: Reverse
T3, Biochem Immuno Systems).
Statistical analysis
Student’s t-test for paired and unpaired data was used to
compare values between groups statistically. All data are
expressed as the mean+s.e.mean; dierences were considered
significant when P values were less than 0.05.
Results
Chronic treatment
ECG in conscious dogs For 4 weeks dogs were given
capsules filled with 25 mg kg71 dronedarone twice a day
(morning and afternoon) or capsules filled with 50 mg kg71
amiodarone once a day (morning). Before the drug treatment
ECG (limb leads I – III) records were taken in the conscious
dogs. The recordings were repeated after 4 weeks of
treatment 1 – 2 h before sacrificing the animals for the cellular
electrophysiological measurements. The results are summar-
ized in Table 1. After chronic treatment with amiodarone the
PQ, QT, QRS and QTc intervals were significantly increased.
After chronic dronedarone treatment the QRS and QTc
intervals did not change considerably. The PQ interval and
the sinus cycle length (CL) were, however, significantly
prolonged. Obviously as a result of this latter eect, the
QT interval was also lengthened by chronic treatment with
dronedarone.
Eects on action potential characteristics in dog ventricular
muscle and Purkinje fibres The eect of chronic dronedarone
and amiodarone treatment on the action potential parameters
in dog ventricular papillary muscle and Purkinje fibres at
constant 1 Hz stimulation frequency is summarized in Table
2. Chronic dronedarone treatment did not alter the action
potential parameters either in papillary muscle or in Purkinje
fibres, except for a slight diminution of the maximal diastolic
potential (MDP). In papillary muscle obtained from
chronically amiodarone treated dogs APA and Vmax values
were less, the APD90 was longer than those measured in
muscles isolated from nontreated control dogs. In Purkinje
fibre preparations none of the action potential parameters
were dierent from those in the control fibres with the
exception of MDP, which was slightly less negative in
Purkinje fibres obtained from the amiodarone treated group
compared with control.
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Frequency dependent eects in dog ventricular muscle and
Purkinje fibres The frequency dependent eects of chronic
dronedarone and amiodarone treatment on the APD and
Vmax in ventricular papillary muscle and in Purkinje fibres
are shown in Figure 1 and Figure 2, respectively. In
papillary muscle chronic dronedarone treatment did not
change significantly the APD in the physiological range of
stimulation cycle lengths corresponding to the heart rate that
may occur in vivo i.e. between 300 ms and 1000 ms, but at
slow cycle lengths (1500 – 2000 ms) the APDs tended to be
longer than those in the untreated control preparations. In
contrast, after chronic amiodarone treatment, at all cycle
lengths, the APD values were significantly longer than those
in the control group. In papillary muscle chronic dronedar-
one treatment caused a weak but significant (P50.05)
decrease of Vmax at cycle lengths shorter than 1000 ms
when compared to control. Chronic amiodarone treatment
however resulted in a marked significant frequency depen-
dent depression of Vmax, particularly at cycle lengths shorter
than 1000 ms. The majority of the papillary muscles
obtained from dogs chronically treated with amiodarone
did not follow stimulation at cycle lengths of 300 and
400 ms presumably because of the marked change in the
exitability due to depression of the sodium current at these
high frequencies. APDs measured in Purkinje fibres obtained
from dogs chronically treated with dronedarone and
amiodarone did not significantly dier from those deter-
mined in Purkinje fibres isolated from untreated control
animals. The Vmax values measured in the chronically
amiodarone treated Purkinje fibres were significantly less
than those in the control fibres especially at cycle lengths
shorter than 1000 ms. No such change was obvious in the
dronedarone treated Purkinje fibres.
The use dependent Vmax block after chronic amiodarone
and dronedarone treatment was further studied in papillary
muscle by determining the oset (recovery) and onset kinetics
of Vmax block. The oset kinetics of Vmax block was tested at
the basic cycle length of 1000 ms. After every 20th basic
stimulus an extra stimulus was delivered by gradually
increasing coupling intervals after the end of the eective
refractory period. Diastolic interval was defined as the time
between the 90% repolarization of the basic action potential
and the upstroke of the action potential evoked by the extra
stimulus. As Figure 3A shows, in papillary muscles isolated
from untreated control and chronically dronedarone treated
dogs the Vmax almost completely recovered after 30 – 50 ms
diastolic interval. In contrast, in papillary muscles obtained
from chronically amiodarone treated animals (Figure 3A) the
recovery of Vmax was considerably delayed, i.e., in early
extrasystoles the amplitude of Vmax was less than that during
late diastole. The corresponding recovery of Vmax time
constant value in the muscle preparations isolated from
amiodarone-treated dogs could be well fitted with single
exponential, starting the procedure at 40 ms diastolic
interval. The recovery of Vmax could be characterised by a
time constant of 549.6+43.4 ms (n=5).
The onset kinetics of Vmax block was tested after 1 min
stimulation free period, by applying a 40 beat train of stimuli
with cycle length of 400 ms. Figure 3B shows that in
chronically dronedarone treated preparations, as in untreated
controls, there was only a moderate and relatively slow
decrease of Vmax during the train, which was fitted with single
Table 1 Eect of chronic dronedarone and amiodarone treatment on the ECG parameters in conscious dogs
CL PQ QRS QT QTc
Treatment (ms) (ms) (ms) (ms) (ms)
Control 513.3+17.8 123.4+3.7 51.0+1.5 195.6+3.3 273.6+3.5
n=10
Dronedarone 616.8+36.5* 142.6+6.5* 52.8+1.5 208.5+4.8* 267.9+6.9
2625 mg/kg/day p.o. 4 weeks
Control 543.1+31.4 114.0+6.9 51.0+3.7 189.0+5.5 257.6+7.9
n=6
Amiodarone 655.3+72.4 137.0+10.6* 60.7+1.1* 235.0+1.1* 294.3+10.2*
50 mg/kg/day p.o. 4 weeks
n=6
CL=sinus cycle length. *P50.05.
Table 2 Eect of chronic dronedarone and amiodarone treatment on the action potential characteristics in dog right ventricular
papillary muscle and Purkinje fibre
MDP APA APD50 APD90 Vmax
Treatment n (mV) (mV) (ms) (ms) (V×s71)
Ventricular muscle
Control 23 785.1+0.7 108.3+0.7 201.4+3.5 234.6+3.3 223.3+8.5
Chronic dronedarone 18 784.1+0.6 105.3+1.3 198.6+5.1 240.0+5.9 210.2+9.5
Chronic amiodarone 15 782.1+0.8 101.5+1.4* 209.1+4.2 251.7+8.2* 171.9+8.2*
Purkinje fibre
Control 19 787.8+0.6 121.0+0.9 244.4+10.3 325.4+9.0 487.1+21.3
Chronic dronedarone 9 784.6+0.9* 116.9+2.3 233.4+20.2 344.4+20.2 435.8+38.9
Chronic amiodarone 8 783.5+1.1* 116.1+2.3 188.0+18.0 323.9+12.0 437.9+43.7
Stimulation frequency=1 Hz; MDP=maximal diastolic potential; APA=action potential amplitude; APD50=action potential duration
(50 and 90% repolarization time); Vmax=maximal rate of depolarization; *=P50.05.
British Journal of Pharmacology vol 133 (5)
Electrophysiological effects of dronedaroneA. Varro´ et al628
exponential characterized by the rate constants of
8.9+0.5 ms (n=19) and 10.9+0.7 ms (n=17), respectively.
In contrast, in papillary muscles obtained from chronically
amiodarone treated dogs there was a marked Vmax change
during the train. As Figure 3B indicates the onset kinetics of
Vmax block could be best fitted with double exponential. In
addition to the rate constant of the slow component
(17.0+3.9, n=4) another fast rate constant (1.56+0.13,
n=4) with a relatively large amplitude could also be
determined.
Acute superfusion
Eects on action potential characteristics in dog ventricular
muscle and Purkinje fibres The eects of acute dronedar-
one and amiodarone superfusion on the action potential
parameters in dog right ventricular papillary muscle and
Purkinje fibres are shown in Figure 4 and summarised in
Table 3. At stimulation cycle length of 1000 ms the eects
of dronedarone and amiodarone were very similar to each
other in papillary muscle, i.e. both drugs moderately
lengthened repolarization measured as APD50 and APD90
without significantly changing other action potential
parameters as MDP, APA and Vmax. However, dronedar-
one and amiodarone, presumably due to their I/B type
sodium channel blocking activity, exerted some moderate
but statistically significant (P50.05) use dependent Vmax
depression at stimulation cycle lengths shorter than
1000 ms in both papillary muscle (at cycle length of
300 ms, from 206.7+12.8 V·s71 to 178.1+9.9 V·s71
(n=12) for 10 mM dronedarone, and from 211.5+8.6
V·s71 to 178.5+12.3 V·s71 (n=8) for 10 mM amiodarone,
and Purkinje fibre (at cycle length of 300 ms, from
437.4+37.5 V·s71 to 351.6+53.1 V·s71 (n=7) for 10 mM
dronedarone and from 392.8+22.9 V·s71 to 306.4+36.7
V·s71 (n=5) for 10 mM amiodarone). In our previous
experiments we observed that the solvent (DMSO), at
concentrations corresponding to the concentration of
Figure 3 The eects of chronic dronedarone and amiodarone
treatment on the oset (A) and onset (B) kinetics of Vmax block in
dog right ventricular papillary muscle. In B, Vmax value is expressed
as fraction of the first Vmax in the train. For the sake of clarity sign
of significance was omitted. Bars represent+s.e.mean.
Figure 4 The eect of acute dronedarone (10 mM) and amiodarone
(10 mM) superfusion on the action potentials in dog right ventricular
papillary muscle and cardiac Purkinje fibre. The stimulation
frequency: 1 Hz; and the incubation time: 60 min.
Figure 1 The frequency dependent eects of chronic dronedarone
and amiodarone treatment on the action potential duration (APD)
(A) and the maximal upstroke velocity (Vmax) (B) in dog right
ventricular papillary muscles. Asterisks denote statistically significant
(P50.05) changes from control. Bars represent+s.e.mean.
Figure 2 The frequency dependent eects of chronic dronedarone
and amiodarone treatment on the action potential duration (APD)
(A) and the maximal upstroke velocity (Vmax) (B) in dog cardiac
Purkinje fibres. Asterisks denote statistically significant (P50.05)
changes from control. Bars represent+s.e.mean.
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DMSO applied as a solvent for 10 mM dronedarone, did
not change significantly any of the action potential
characteristics. In dog right papillary muscle both 10 mM
dronedarone and 10 mM amiodarone moderately prolonged
repolarisation (Table 3), but in Purkinje fibres both
dronedarone and amiodarone superfusion significantly
shortened repolarisation measured as APD50 and APD90
and reduced Vmax to various degrees, without significant
change of the MDP and APA (Table 3).
Eects on early and delayed afterdepolarization in dog cardiac
Purkinje fibres The eects of acute dronedarone and
amiodarone superfusion on the early afterdepolarization
(EAD) and delayed afterdepolarization (DAD) were studied
in dog left ventricular Purkinje fibres. EADs were evoked by
20 – 40 min superfusion with 1 mM dofetilide. The stimulation
frequency was gradually decreased from 1 to 0.08 Hz until
EAD or spontaneous beat developed. Once EADs appeared,
they persisted for more than 2 h as verified in separate
control experiments. The incidence of EADs was calculated
during a train of 30 beats before and after 40 – 60 min
superfusions of 10 mM dronedarone or 10 mM amiodarone. In
the presence of dronedarone and amiodarone the incidence,
i.e. the ratio of the action potentials showing EADs versus
normal beats without EADs, significantly decreased from
77.8+3.8% to 11.7+2.8% (n=6; P50.05) and from
58.6+4.5% to 8.0+3.2% (n=5; P50.05), respectively
(Figure 5).
To evoke delayed afterdepolarization (DAD) the prepara-
tions were driven by 2 Hz frequency interrupted by 2 min
stimulation free periods. In the absence of ouabain, after
cessation of the stimulation, DADs never occurred (Figure
6). In the presence of 0.2 – 0.3 mM ouabain for 40 – 60 min,
after abrupt termination of the stimulation, DADs developed
with amplitudes ranging from 4.7 to 13.7 mV (Figure 5).
DADs were persistent in the presence of ouabain for more
than 2 h as tested in separate experiments. After the DADs
had been evoked, the preparations were superfused with
10 mM dronedarone or 10 mM amiodarone for 30 – 40 min.
Both dronedarone and amiodarone abolished or significantly
decreased the amplitudes of the ouabain induced DADs from
10.2+0.4 to 1.8+0.6 mV (n=5; P50.05) and from
11.1+0.7 mV to 2.4+0.5 mV (n=5; P50.05) respectively
(Figure 6).
Table 3 Eect of acute exposure to dronedarone and amiodarone on the action potential characteristics in dog right ventricular
papillary muscle and Purkinje fibre
MDP APA APD50 APD90 Vmax
Drug n (mV) (mV) (ms) (ms) (V×s71)
Ventricular muscle
Control 785.7+0.8 109.1+0.7 207.1+5.2 239.6+5.3 226.2+13.0
Dronedarone, 10 mM 13 784.3+0.7 108.5+0.9 216.4+5.1* 248.6+5.3* 222.6+10.9
Control 782.4+0.9 106.4+0.8 184.5+4.5 213.2+4.2 230.0+7.8
Amiodarone, 10 mM 10 784.3+0.7 108.2+1.0 197.3+4.9* 229.0+5.0* 219.8+12.3
Purkinje fibre
Control 786.3+1.7 119.6+2.1 239.6+12.6 309.6+11.8 470.6+35.8
Dronedarone, 10 mM 7 785.3+1.6 116.3+1.5 188.1+15.0* 287.1+10.8* 445.0+54.8
Control 787.7+1.7 119.2+1.7 225.5+17.4 307.0+16.5 421.0+15.3
Amiodarone, 10 mM 6 783.8+1.1 113.5+3.7 182.2+11.7* 279.7+11.9* 370.0+27.1*
Stimulation frequency=1 Hz; MDP=maximal diastolic potential; APA=action potential amplitude; APD50790=action potential
duration (50 and 90% repolarization time); Vmax=maximal rate of depolarization; *=P50.05.
Figure 5 The eect of acute dronedarone and amiodarone super-
fusion on the early afterdepolarization (EAD) in dog cardiac left
ventricular Purkinje fibres. EADs were evoked by 1 mM dofetilide at
stimulation cycle length of 5000 ms. After superfusion with either
10 mM dronedarone or 10 mM amiodarone in the continuous presence
of dofetilide, EADs were abolished.
Figure 6 The eect of acute dronedarone and amiodarone super-
fusion on the delayed after depolarisation (DAD) in dog cardiac left
ventricular Purkinje fibres. DADs were evoked by 0.2 – 0.3 mM
ouabain at stimulation cycle length of 500 ms. After superfusion
with either 10 mM dronedarone or amiodarone in the continuous
presence of ouabain, DADs were abolished.
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Eects on transmembrane ionic currents in dog ventricular
myocytes Since the ECG recordings showed lengthening
of the PQ interval and the action potential measurements
suggested inhibition of the repolarization after dronedarone
application, the eect of 10 mM dronedarone on the
various transmembrane ionic currents was also studied in
single dog ventricular myocytes to elucidate the mechan-
isms of the dronedarone induced electrophysiological
changes.
L-type inward calcium current (ICa) was evoked by 400 ms
long depolarizing test pulses (ranging from 730 to +60 mV)
from 740 mV holding potential. The amplitude of ICa was
defined as the dierence between the peak inward current at
the beginning of the pulse and the current at the end of the
pulse. In these measurements the KCl content of the pipette
was replaced by CsCl to suppress potassium currents. As
Figure 7 shows, 10 mM dronedarone, after 5 min superfusion,
largely decreased ICa. The magnitude of the ICa depression at
0 mV was 76 % (from 1137.7+299.1 pA to 270.5+70.5 pA,
n=6, P50.05), which was only partially reversible even after
10 min washout.
The possible eect of 10 mM dronedarone superfusion on
the dierent potassium currents was also investigated. In
these measurements the extracellular solution contained 1 mM
nisoldipine to completely block ICa.
The transient outward potassium current (Ito) and the
inward rectifier potassium current (Ikl) were activated from
holding potential of 780 mV by 400 ms test pulses ranging
from 7120 to +60 mV. The amplitude of Ito was determined
as the dierence current between the peak outward current at
the beginning and the steady-state current at the end of the
pulse. Ikl was defined as the amplitude of the steady-state
current at the end of the pulse. As Figure 8 shows, 10 mM
dronedarone did not apparently and significantly influenced
the amplitude of Ito and Ikl after 5 – 8 min superfusion.
The slow (IKs) and rapid (IKr) components of the delayed
rectifier outward potassium current were activated from
740 mV holding potential with 1 s (IKr) and 5 s (IKs)
depolarizing test pulses of 720 to +60 mV at pulse
frequency of 0.01 Hz. To define IKs and IKr, after returning
the voltage to 740 mV, the amplitude of the tail current was
determined. When the eect of dronedarone on the IKs was
studied, the extracellular solution contained 1 mM E-4031 and
when IKr was examined, the extracellular solution contained
30 mM chromanol 293B to block IKr and IKs selectively,
thereby allowing proper separation of the two currents. As
Figure 8 shows, 10 mM dronedarone did not significantly
change the amplitude of the IKs tail current. In contrast,
10 mM dronedarone almost completely depressed the IKr tail
current (Figure 9).
Plasma and tissue concentrations Dogs receiving daily
50 mg kg71 amiodarone for 4 weeks had amiodarone and
desethylamiodarone plasma levels of 7.87+1.74 mg ml71 and
1.01+0.17 mg ml71 respectively (n=6). The corresponding
tissue (heart) concentrations were 6.71+1.5 mg mg71 and
7.12+1.53 mg mg71. Dogs receiving daily 2625 mg71 kg71
day dronedarone had 1.01+0.32 mg ml71 plasma and
10.68+4.51 mg mg71 cardiac tissue concentration of the
parent drug (n=7), and 0.09+0.03 mg ml71 plasma and
2.04+0.69 mg ml71 cardiac tissue concentration of the N-
debuthyl metabolite.
Plasma thyroid hormones concentrations T4, T3 and reverse
T3 (rT3) levels in the plasma were measured after 4-week
treatment with amiodarone and dronedarone. In comparison
Figure 7 The eect of 10 mM dronedarone on the inward calcium
current (ICa) in single dog ventricular myocyte. (A) shows original
recordings from a representative experiment. (B) indicates the voltage
current relation before (*) and after (*) dronedarone (10 mM for 3 –
5 min) superfusion in an average of six cells. Bars indicate+s.e.mean.
Figure 8 The eect of (A) 10 mM dronedarone on the transient
outward potassium (Ito), (B) the inward rectifier potassium (Ikl), and
(C) the slow component of the delayed rectifier outward potassium
current (IKs) in single dog ventricular myocyte. The left side of each
panel shows the original recording obtained in a representative
experiment. On the right side the current voltage relations are
illustrated before (*) and after the application of 10 mM dronedarone
(*) superfusion in an average of 5 – 6 cells. Bars indicate+s.e.mean.
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with the control group, amiodarone induced a decrease in T3
and an increase in the T4·T3
71 ratio and rT3. Dronedarone
did not modify significantly T4, T3 or rT3 levels (Table 4).
Discussion
Major findings
The major findings of this study indicate that: (a)
Dronedarone, unlike amiodarone, does not produce con-
siderable repolarization lengthening in dog ventricular muscle
after chronic treatment. (b) Acute dronedarone superfusion,
like acute exposure to amiodarone, moderately shortens
repolarization in the Purkinje fibres but only moderately
lengthens it in the ventricular muscle. (c) Acute dronedarone
application results in a mild use-dependent Vmax depressing
and strong ICa and IKr inhibitory eects. (d) Acute
dronedarone superfusion diminishes both types of triggered
arrhythmogenic automaticity (EAD and DAD).
Comparison with previous reports
In our study the eects of both acute and chronic
amiodarone application are similar to those published earlier
by others (Sicouri et al., 1997; Kato et al., 1988; Mason et al.,
1984; Anderson et al., 1989).
Our study shows that chronic dronedarone treatment does
not lengthen the repolarization. These results are in good
agreement with those of Finance et al. (1998) and Barthelemy
et al., (1998a,b) who observed that dronedarone, in a similar
range of doses, did not change QTc. These authors, as well as
Merot et al. (1999) found that amiodarone also does not
induce a significant QTc prolongation, demonstrating that
amiodarone-induced QTc lengthening is not always observed
in dogs.
Recently Sun et al. (1999) reported that in the rabbit
chronic dronedarone treatment caused similar and even more
pronounced electrophysiological eects than those produced
by long-term administration of amiodarone. Based on these
results the authors speculated that iodine in the chemical
structure –which was believed to be responsible for many of
the unwanted side eects of amiodarone –was not a necessity
to produce the ‘amiodarone like’ chronic electrophysiological
eects. Our present results obtained in dogs are dierent, and
our conclusion is in sharp contrast with those of Sun et al.
(1999), since in our hands, chronic dronedarone treatment
did not result in convincing ‘amiodarone like’ electrophysio-
logical eects. Therefore, our data support previous specula-
tions that iodine in the molecular structure is probably
needed to cause the characteristic ‘amiodarone like’ chronic
electrophysiological changes.
Also, closer inspection of Table 2 in the study of Sun et
al. (1999) reveals that the APD values in the control group
of the chronic experiments were 130 ms, significantly
shorter than those in the amiodarone (172 ms) and
dronedarone (183 ms) pretreated groups. However, Figure
7 of the same report, in which the acute eect of
dronedarone and amiodarone is presented on the APD,
shows that in another control group (before dronedarone
and amiodarone superfusion) APD was 193 – 205 ms, i.e.
longer than that after chronic dronedarone and amiodarone
treatment in Table 2. Furthermore, after chronic treatment
we found strong use-dependent Vmax block with amiodar-
one but not with dronedarone. In contrast, Sun et al.
(1999) observed a larger but apparently not use-dependent
Vmax depression after chronic dronedarone than after
chronic amiodarone treatment. Although the dierences in
dosage, experimental conditions and species may be of
some significance, we can not fully explain this discrepancy
between the results of Sun et al. (1999) and our own
findings.
Despite the described dierences between our observations
and the results of Sun et al. (1999), our in vivo (ECG)
findings with dronedarone virtually confirm the earlier results
of Manning et al. (1995b) also obtained in dogs. It was also
found (Verduyn et al., 1999) that in anaesthetized dogs with
chronic A-V block i.v. dronedarone abolished almokalant
induced EADs and torsade de pointes tachycardia, a finding
which is consistent with the result of our similar in vitro
measurement.
Figure 9 The eect of 10 mM dronedarone on the rapid component
of the delayed rectifier outward potassium current (IKr) in single dog
ventricular myocyte. (A) shows original recordings from a repre-
sentative experiment. (B) indicates the voltage current relation before
(*) and after (*) dronedarone (10 mM for 3 – 5 minutes) superfusion
in an average of six cells. Bars indicate+s.e.mean.
Table 4 Thyroid hormone levels after 4-week oral treatment with dronedarone and amiodarone
T4 T3 rT3
Drug (pmol×ml71) (pmol×ml71) T4/T3 (fmol×ml71)
Control 24.9+2.8 1.03+0.1 24+2 705+100
Dronedarone 2625 mg71 kg71 day 22.1+2.8 0.99+0.12 21+2 595+82
Amiodarone 50 mg kg71 day 32.0+3.8 0.62+0.11* 56+7** 1390+194**
Mean+s.e.mean. *P50.05; **P50.01 versus control
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On the other hand our in vitro results with dronedarone are
in good agreement with those of Moro et al. (1999) since we
have also found only moderate or at cycle lengths shorter
than 1000 ms use-dependent Vmax block after acute drone-
darone superfusion.
Possible mechanism of the effect of dronedarone
The observed lack of considerable electrophysiological eect
of chronic dronedarone treatment is an important finding.
Insucient absorption of the drug is not a cause, since the
compound has good bioavailability and yielded significant
concentration both in the plasma and in the heart.
Dronedarone, unlike amiodarone, does not aect the level
of thyroid hormones. Moreover, dronedarone and N-
debutyldronedarone have weak anity to human nuclear
thyroid hormone receptors, slightly inferior to those of
amiodarone (M. Delbruye`re, 2001, unpublished results), i.e.
it is much less than DEA anity (Latham et al., 1987). These
observations suggest that the inhibition of the thyroid
hormone metabolism and/or the blockade of the thyroid
hormone receptors during the chronic treatment with
amiodarone are likely due to the accumulation of DEA in
the tissues rather than to the presence are absence of iodine
ions in the parent molecule. Furthermore, the decrease of T3
by DEA may aect the potassium channel protein synthesis
leading to a decreased density of dierent potassium channels
(Varro´ et al., 1996; Kodama et al., 1997; 1999; Bosch et al.,
1999). It has to be mentioned that in the present study, after
chronic dronedarone treatment, some APD lengthening was
observed in the right ventricular papillary muscle, at
stimulation cycle lengths longer than 1000 ms (Figure 1).
However, at more physiological rates the APD lengthening
was not present after chronic dronedarone treatment or it
was too small to measure. In in vivo ECG measurements,
where the spontaneous cycle length of the dogs was about
500 – 600 ms, no significant QTc prolongation was found.
These findings suggest that the observed dierences in the
chronic electrophysiological eects between dronedarone and
amiodarone are most probably due to the lack of iodine in
the chemical structure of dronedarone.
On the basis of the high degree of IKr block observed in
isolated ventricular myocytes after acute dronedarone
application we could have expected more pronounced APD
lengthening. It is not clear why the strong IKr block caused
by dronedarone was not associated with more marked APD
prolongation in papillary muscle. The conditions for drug
diusion are certainly better in the patch clamp than in the
conventional microelectrode experiments. Also, one may
speculate that dronedarone, like amiodarone, has multiple
sites of action involving other ionic channels (Nattel, 1993;
Kodama et al., 1997), such as the L-type calcium (Nishimura
et al., 1989) and inward sodium channels which, by carrying
depolarizing currents, may oppose the APD lengthening
eect of the IKr block. This is definitely more pronounced in
Purkinje fibres where these latter currents play more
important role, but this mechanism is also likely to operate
in the ventricular muscle.
The dronedarone induced sodium channel block is weaker
than that evoked by amiodarone, but this may have an
advantageous consequence. Dronedarone, like amiodarone
and unlike the ‘pure’ IKr blocker d-sotalol, may decrease the
dispersion of repolarisation between ventricular muscle and
Purkinje fibres. If this type of dispersion is augmented in
pathophysiological situations (e.g. myocardial infarction,
long QT syndrome, hypokalaemia), it may facilitate the
onset of life-threatening arrhythmias, such as ‘torsade de
pointes’; polymorphic ventricular tachycardia. Therefore
drugs that decrease such an enhanced dispersion may have
considerable advantage. Since the dronedarone induced
sodium channel depression is not strong and does not result
in substantial Vmax block and slowing of the impulse
conduction, with this drug the likelihood of the development
of the CAST type proarrhythmia, which is associated with
drug induced conduction disturbances, is less likely with
dronedarone than with other more potent sodium channel
blockers, including even amiodarone. Furthermore, since the
dronedarone induced reduction and suspension of DAD and
EAD is supposedly due to the drug-related inhibition of the
sodium and particularly the calcium channels, similar
argument may be valid to interpret the beneficial eect of
dronedarone on the DAD and EAD, when suppressing these
afterdepolarizations.
Conclusion
It can be concluded that after acute administration the
cardiac electrophysiological eects of dronedarone are similar
to those of amiodarone, which may at least partly explain its
in vivo antiarrhythmic eect. However, after long-term
administration dronedarone, unlike amiodarone, does not
produce marked electrophysiological changes. On chronic
administration N-debutyl dronedarone, the main metabolite
of dronedarone does not reach electrophysiologically active
plasma and cardiac tissue levels, whereas N-desethylamiodar-
one, the highly potent principal metabolite of amiodarone,
accumulates in cardiac tissue. One might therefore speculate
that N-desethylamiodarone could be, at least in part,
responsible for the dierence in the chronic electrophysiolo-
gical eects of dronedarone and amiodarone.
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